A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
← catalyst calendarNCT07206472 · readout in 826 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
2,120estimated
Sites
23
Countries
Brazil, Hong Kong
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-03 | actual | When the study began enrolling |
| Primary completion | 2028-11-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Primary Hypercholesterolaemia
- Mixed Dyslipidemia
Intervention
- Drug: Combination of bempedoic acid and ezetimibe
Primary outcome
what the primary-completion date above is the date OFIncidence of adverse events
measured From pre-bempedoic acid/pre-FDC initiation to 1 year after initiation of therapy
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed